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Immunotherapy for Infarcts:
In Vivo Postinfarction Macrophage Modulation
Using Intramyocardial Microparticle Delivery
of Map4k4 Small Interfering RNA
Jun Luo,1,{ Matthew S. Weaver,1,{,{ Timothy P. Fitzgibbons,2 Myriam Aouadi,3
Michael P. Czech,4 and Margaret D. Allen1,5,*
Abstract
The myeloid cells infiltrating the heart early after acute myocardial infarction elaborate a secretome that largely
orchestrates subsequent ventricular wall repair. Regulating this innate immune response could be a means
to improve infarct healing. To pilot this concept, we utilized (b1,3-D-) glucan-encapsulated small interfering
RNA (siRNA)-containing particles (GeRPs), targeting mononuclear phagocytes, delivered to mice as a one-time
intramyocardial injection immediately after acute infarction. Findings demonstrated that cardiac macrophages
phagocytosed GeRPs in vivo and had little systemic dissemination, thus providing a means to deliver local ther-
apeutics. Acute infarcts were then injected in vivo with phosphate-buffered saline (PBS; vehicle) or GeRPs loaded
with siRNA to Map4k4, and excised hearts were examined at 3 and 7 days by quantitative polymerase chain re-
action, flow cytometry, and histology. Compared with infarcted PBS-treated hearts, hearts with intrainfarct injec-
tions of siRNA-loaded GeRPs exhibited 69–89% reductions in transcripts for Map4k4 (mitogen-activated protein
kinase kinase kinase kinase 4), interleukin (IL)-1b, and tumor necrosis factor a at 3 days. Expression of other factors
relevant to matrix remodeling—monocyte chemoattractant protein-1 (MCP-1), matrix metalloproteinases, hyalur-
onan synthases, matricellular proteins, and profibrotic factors transforming growth factor beta (TGF-b), and con-
nective tissue growth factor (CTGF)—were also decreased. Most effects peaked at 3 days, but, in some instances
(Map4k4, IL-1b, TGF-b, CTGF, versican, and periostin), suppression persisted to 7 days. Thus, direct intramyocardial
GeRP injection could serve as a novel and clinically translatable platform for in vivo RNA delivery to intracardiac
macrophages for local and selective immunomodulation of the infarct microenvironment.
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Introduction
Macrophages and monocytes (M/Ms) accumulate rap-
idly in the heart after acute myocardial infarction
(AMI) and largely orchestrate postinfarct ventricular
remodeling1,2 ; yet, current therapies have not addressed
this innate immune response. The first wave of infiltrating
M/Ms elaborate proinflammatory cytokines that trigger
degradation of extracellular matrix and initiate profib-
rotic processes which, unchecked, contribute to ventricu-
lar wall dilatation, interstitial fibrosis, and heart failure.3
1Matrix Biology Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA.
2Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
3Integrated Cardio Metabolic Center, Department of Medicine, Karolinska Institutet, Huddinge, Sweden.
4Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
5Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, Washington, USA.
{Both these authors contributed equally to this work.
{Present address: General Education, Western Governors University, Salt Lake City, Utah, USA.
*Address correspondence to: Margaret D. Allen, MD, Matrix Biology Program, Benaroya Research Institute at Virginia Mason, 1201 Ninth Avenue, Seattle, WA 98101-2795,
USA, E-mail: vgreen@benaroyaresearch.org
ª Jun Luo et al., 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original




Accepted October 21, 2020
BioResearch
O P E N A C C E S S
258
Thus, modulating the behavior of this early intracardiac
myeloid population could provide an opportunity to in-
fluence and optimize postinfarct myocardial recovery.
These pilot experiments explored whether glucan-
encapsulated small interfering RNA (siRNA)-containing
particles (GeRPs), developed by Czech and col-
leagues,4–7 could be utilized for in situ modification of
M/Ms within the heart. The b1,3-D-glucan shells of
these 2–4 lm-sized particles bind dectin-1 receptors
on phagocytes,8 selectively targeting siRNA uptake to
M/Ms.5 Furthermore, RNA interference (RNAi) screen-
ing previously identified the silencing of Map4k4
(mitogen-activated protein kinase kinase kinase kinase
4) as being particularly effective at downregulating
inflammatory cytokine release in peritoneal macro-
phages.4 An 8-day course of orally delivered GeRPs
resulted in efficient particle ingestion by macrophages
in gut-associated lymphoid tissues, which then traf-
ficked to systemic lymphatic organs. Map4k4 knock-
down inhibited interleukin (IL)-1b and tumor necrosis
factor (TNF)-a production in peritoneal macrophages,
significantly reduced systemic inflammatory signaling,
and protected mice from LPS-induced lethality.4
Courses of intraperitoneally and intravenously delivered
GeRPs, using other siRNAs, have effectively silenced in-
flammatory genes in adipose macrophages and Kupffer
cells, ameliorating insulin resistance.7,9
However, for the AMI setting, the objective was instead
to selectively target M/Ms within the heart, not systemi-
cally, to achieve a local, time-limited dampening of
early inflammatory responses within the infarct. We hy-
pothesized that injecting a single dose of siRNA-loaded
GeRPs directly into the infarct site would create a repos-
itory of intramyocardial particles encountered only by the
early M/Ms infiltrating the heart, and cardiac-resident
macrophages. Specifically, we examined whether intra-
cardiac M/Ms would phagocytose GeRPs deposited in
acute infarcts; whether macrophages with ingested parti-
cles would remain in the heart or return to the circulation;
and whether a single dose of Map4k4-directed siRNA
could modify M/M secretory profiles across the entire
myocardium, recognizing that only a fraction of the intra-
cardiac M/M population would take up particles.
Methods
Animals
Animal protocols were approved by the Institutional
Animal Care and Use Committee under NIH guide-
lines. C57BL/6J mice, age 7–9 weeks, 20–26 g, were
purchased from Jackson Laboratory.
Particles
GeRPs were prepared as described previously.4–7 In
brief, hollow glucan shells, 2–4 lm diameter, produced
from Saccharomyces cerevisiae cell walls, were labeled
with 5-DTAF [5-(4, 6-dichlorotriazinyl) aminofluores-
cein; ThermoFisher]. For siRNA loading, 10 lL of
1 mM siRNA were combined with 85 lL of sodium ac-
etate (30 mM), then added to 94 lL of 5 mM Endoporter
(Gene Tools), and incubated at room temperature for
15 min. Ten milligrams of glucan shells were added, in-
cubated for 1 h at room temperature, and then diluted in
phosphate-buffered saline (PBS) to 1.5 mL. Particles
were stored at 80C and sonicated before use. Heart
injectates of empty particles (no siRNA) utilized a
dose of 2.7 · 108 b-glucan shells/heart. Injectates of
siRNA-loaded particles consisted of 5 · 107 GeRPs in
10 lL PBS, containing 50 pmol Map4k4 siRNA, calcu-
lated to provide 10 GeRPs/macrophage, based on
4 · 106 F4/80+ macrophages/heart measured on day 2





Under isoflurane anesthesia with mechanical ventila-
tion, AMIs were created through left thoracotomies
by left anterior descending coronary ligation (without
reperfusion). Five minutes later, a single 10 lL injection
of PBS, empty GeRPs (no siRNA), or siRNA-loaded
GeRPs was made directly into the infarct center using
a 30G needle. At terminal surgery, mice were re-
anesthetized with isoflurane for tissue collection.
Flow cytometry
After heparinization, peripheral blood, spleen, heart,
and femurs were collected. Hearts were perfused with
2 mL 4C St. Thomas’ cardioplegia solution, atria dis-
carded, and the entire ventricle minced, then sus-
pended in 8–10 mL lysis buffer (10 mM HEPES,
30 mM taurine, and 0.2 mg/mL Liberase TH protease
cocktail [Roche] in HBSS [1 · ]). The suspension was
filtered (40 lm strainer) into digestion-stopping buffer
(10 mM HEPES, 30 mM taurine, diluted 1:10 with heat-
inactivated fetal bovine serum). Spleen tissue and bone
marrow were similarly filtered. Heart, spleen, and
marrow-isolated cells were pelleted by centrifugation
(5 min, 1000 · g, 4C), incubated in erythrocyte lysis
buffer (BioLegend), re-pelleted and washed in 1 mL
cell staining buffer (BioLegend), centrifuged and
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resuspended in 50 lL of staining buffer containing rat
anti-mouse antibodies against CD11b (M1/70, PerCP/
Cy5.5-conjugated), F4/80 (BM8, PE-conjugated), and
Ly-6C (HK1.4, PE-Cy7-conjugated; all BioLegend).
Twenty thousand events were collected/sample on the
flow cytometer (LSRII; BD Biosciences), and analyzed
with FlowJo v10.0.7 (Tree Star). Macrophages were
defined as CD11bhigh/F4/80high with internalized
GeRP particles identified by fluorescein labels. Ly6C
expression was categorized as high, intermediate, or
low, reporting CD11bhigh/F4/80high macrophages
with high and low Ly6C expression. Macrophages
with intermediate intensity Ly6C labeling, often com-
prising a majority of cells, were not included in this
polarized analysis.
Quantitative polymerase chain reaction
Mouse hearts were perfused with 2 mL 4% paraformal-
dehyde (PFA) at 4C, excised, atria discarded, and the
right and left ventricles (infarcted plus noninfarcted
myocardium), placed in RNAlater (Qiagen), and stored
at 80C. After thawing, the RNeasy Fibrous Tissue
Mini Kit (Qiagen) was utilized, placing tissue in
300 mL RLT buffer (Qiagen), then homogenizing
for 45–60 sec (Omni TH; OMNI International). RNA
concentration was determined on a NanoDrop spectro-
photometer (ThermoFisher) and 1 lg RNA used as
template in a 50 lL reverse transcription polymerase
chain reaction (PCR) using a High Capacity comple-
mentary DNA (cDNA) Reverse Transcription Kit
(Applied Biosytems). Subsequently, 1 mL of each
cDNA sample was used as a template in quantitative
PCR with primers for SYBR Green labeling (for murine
genes encoding Map4k4 [Map4k4], TNF-a [Tnf], IL-1b
[Il1b], monocyte chemoattractant protein-1 [MCP-1,
Ccl2], matrix metalloproteinase [MMP]-1 [Mmp1a],
MMP-2 [Mmp2], MMP-9 [Mmp9], MMP-12 [Mmp12],
insulin-like growth factor-1 [IGF-1, Igf1], Has-1 [Has1],
Has-2 [Has2], HYAL-1 [Hyal1], CD44 [Cd44], connec-
tive tissue growth factor [CTGF, Ctgf], fibronectin
[Fn1], collagen III [Col3a1], SPARC [Sparc], tenascin-
C [Tnc], and periostin [Postn]; Applied Biosystems) or
TaqMan (versican [Vcan], transforming growth factor
beta [TGF-b, Tgfb1], collagen I [Col1a1], IL-10 [Il10],
and 18S ribosomal RNA [rRNA, Rn18s]; Applied Bio-
systems). Reactions were run for 45 cycles and results
read on ABI 7900HT real-time equipment (Applied Bio-
systems). Delta Ct (DCt) was calculated as the fold dif-
ference in cycles (Ct) for the target genes referenced to
the 18S rRNA gene. Relative messenger RNA (mRNA)
levels were calculated by the 2DDCt method10 to express
the fold increase over RNA values in untreated (nonin-
farcted) murine hearts.
Histology
Hearts were perfused in situ with 2mL 4% PFA at 4C,
excised, and placed in 4% PFA at 4C for 24 h, then
washed in 70% EtOH, sliced transversely, paraffin embed-
ded, and sectioned at 5 lm intervals. Immunohistochem-
istry utilized antibodies to F4/80 (Cl:A3–1; Abcam) for
murine macrophages; and TNF-a (52B83; Santa Cruz);
cell nuclei were counterstained with Hoeschst dye
(ThermoFisher). Fluorescein labels identified GeRPs.
Hyaluronan (HA) was visualized by biotin-conjugated
HA-binding protein followed by streptavidin-Texas
Red containing 1% bovine serum albumin.11
Statistical analysis
Mean values were compared between treatment groups
using two-tailed Student’s t tests, or one-way analysis
of variance with Tukey’s post hoc test for multiple com-
parisons. Significance was determined at p < 0.05 and
variance presented as – standard error of the mean.
Results
Acute infarction increases GeRP uptake
by cardiac macrophages
To examine the effects of AMI on GeRP phagocytosis, a
single dose of 2.7 · 108 fluorescein-labeled empty GeRP
particles (without siRNA) was injected into infarct cen-
ters 5 min after infarct creation (n = 4) or into nonin-
farcted left ventricular walls (n = 2). At 7 days, GeRP
uptake across all cardiac macrophages was assessed
by flow cytometry. The prevalence of F4/80high macro-
phages was 60% higher in infarcted versus nonin-
farcted hearts (10% – 2% vs. 6% – 1% of all live cells,
including cardiomyocytes). In infarcted hearts,
53% – 6% of F4/80+ macrophages coexpressed fluores-
cein labels, indicating GeRP phagocytosis, whereas in
noninfarcted hearts, only 10% – 3% were fluorescein la-
beled ( p < 0.01; Supplementary Figs. S1 and S2).
Biodistribution of macrophages
with internalized GeRPs
By 1 week after AMI and intramyocardial GeRP injec-
tion, low percentages of F4/80+ cells with internalized
GeRPs were found in peripheral blood (5% of all live
cells), bone marrow (3%), and spleen (2%). In animals
without infarction, these extracardiac sites had even
lower frequencies of GeRP-containing macrophages
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at 3%, 2%, and 0.4%, respectively. Percentages of F4/
80+ macrophages with internalized GeRPs were signif-
icantly lower in extracardiac sites than in either in-
farcted hearts ( p < 0.0001) or noninfarcted hearts
( p < 0.03; Supplementary Fig. S2). On histology, mac-
rophages within infarcted hearts often contained mul-
tiple GeRPs per cell (Fig. 1), whereas at extracardiac
sites, the few macrophages with internalized GeRPs
usually phagocytosed only single particles (Fig. 1).
Uptake of siRNA-loaded GeRPs by intramyocardial
M/Ms in infarcted hearts
To pilot siRNA delivery to intracardiac macrophages,
single doses of 5 · 107 GeRP particles, containing
50 pg of Map4k4 siRNA (n = 3/group), or PBS (n = 6/
group), were injected into infarct centers 5 min after
AMI. At 3 and 7 days after infarction and injection, ex-
cised hearts were analyzed by FACS to gauge GeRP in-
gestion among CD11b+-gated F4/80+ (macrophage)
FIG. 1. GeRP phagocytosis by macrophages. (A) Representative histologic cross-section of infarcted
myocardium at 7 days after infarction and GeRP injection, demonstrating macrophages with internalized
GeRP particles, as well as free GeRP particles, surrounded by cardiomyocytes. Immunostaining with
antibody to F4/80 identifies macrophages (red), whereas the fluorescein label on GeRPs appears green.
Internalized GeRPs were not observed in somatic cells (i.e., cardiomyocytes). (B, C) Representative cell
isolates from spleen (B) and myocardium (C) at 7 days after infarction, illustrating free and internalized
GeRPs (yellow-green) and macrophages (F4/80+, red staining). Insets show examples of F4/80+ cells with
internalized GeRPs: (C) those from infarcted myocardial tissue have ingested multiple GeRPs per cell in
contrast to the rare, single GeRPs found in splenic macrophages (B). Scale bars demonstrate the relative
paucity of GeRP+ macrophages among splenic (B) versus myocardial (C) cells. GERPs, glucan-encapsulated
small interfering RNA-containing particles.
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and F4/80 (monocyte) populations. At 3 days, 21% – 5%
of cardiac CD11b+/F4/80+ macrophages coexpressed
fluorescein labels, indicating GeRP phagocytosis,
which by 7 days, had dropped to 13% – 3%. Among
CD11b+/F4/80 intracardiac monocytes, a similar per-
centage, 22% – 7%, contained GeRPs by 3 days, which
also diminished to 10% – 4% by 7 days.
Effects of Map4k4-siRNA-loaded GeRPs
on macrophage phenotype
Ly6c expression was examined to explore whether
intramyocardial GeRP delivery would alter phenotypes
across the entire cardiac macrophage population. The
proportion of F4/80+ macrophages among CD11b+
leukocytes was reduced by 20% at both 3 and 7 days
in GeRP-treated infarcted hearts compared with in-
farcted controls ( p = 0.1; Fig. 2). On subset analysis, a
statistically significant switch from predominantly
Ly6chi-expressing macrophages, typically considered a
proinflammatory phenotype,12 to Ly6clo expression,
classically a reparative characteristic,3,13 was evident
in PBS-treated infarcted hearts between the 3- and
7-day time points ( p < 0.01, Fig. 2). Parallel reductions
in Ly6chi-expressing phenotypes ( p < 0.05) and eleva-
tions in Ly6clo-expressing ones ( p = 0.01) were seen
in GeRP-treated hearts (Fig. 2). At both 3 and 7 days,
proportions of M1/M2 macrophage subpopulations
in GeRP-treated hearts were not significantly different
from those in PBS-treated hearts.
Map4k4 silencing after intramyocardial injection
of Map4k4-siRNA-loaded GeRPs
Total cardiac RNA from both ventricles (infarcted plus
noninfarcted myocardium) was analyzed to determine
whether infarct-injected Map4k4-siRNA-containing
GeRPs would impact Map4k4 gene expression across
the heart. Hearts injected with Map4k4-siRNA-loaded
GeRPs (n = 3/group) or PBS (n = 5–6/group) were pro-
cured at 3 or 7 days after infarction; normal hearts
without infarction or surgery served as reference con-
trols (n = 8). Map4k4 transcripts in hearts treated
with Map4k4-siRNA-GeRP injections were reduced
by 86% at 3 days and 89% at 7 days ( p < 0.001) com-
pared with PBS-treated infarcted hearts (Fig. 3).
Effects of Map4k4-siRNA-loaded GeRP delivery
on inflammatory mediators
The same hearts were analyzed for expression of a
panel of factors with known relevance for infarct heal-
ing. Again, transcripts were evaluated over the entire
heart, not just the infarct area, as the end-point most
likely to influence infarct remodeling.
FIG. 2. Prevalence of macrophages and Ly6C-expressing subsets following infarction and intrainfarct GeRP
delivery of Map4k4 siRNA. (A) Percentage of F4/80hi cells, denoting macrophages, among all CD11bhi
leukocytes on FACS analysis of digested whole hearts at 3 and 7 days after infarction and intramyocardial
injection of GeRPs containing Map4k4 siRNA (light gray) or vehicle (dark gray). (B, C) Percentages of Ly6Chi-
and Ly6Clo-expressing cells among the subset of CD11bhi/F4/80hi macrophages at 3 and 7 days in the same
hearts. Data are presented as mean values – SEM. *p < 0.05 versus GeRP-treated infarcted hearts at 3 days;
**p = 0.01 versus GeRP-treated infarcted hearts at 3 days; {p < 0.01 versus PBS-treated infarcted hearts at 3
days. PBS, phosphate-buffered saline; SEM, standard error of the mean; siRNA, small interfering RNA.
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In comparison with infarcted, PBS-treated hearts,
hearts injected with Map4k4-siRNA-loaded GeRPs had
73% lower levels of proinflammatory IL-1b (Il1b) tran-
scripts at 3 days. A 69% reduction persisted out to
7 days ( p = 0.05; Fig. 4). The postinfarct rise in TNF-a
(Tnf) transcription at 3 days was also diminished by
GeRP treatment (75% reduction; Fig. 4). Although dif-
ferences in TNF-a (Tnf) transcription were lost by day
7 in whole heart specimens, evidence of persistent
TNF-a suppression within the local infarct zone was ob-
served on histology (Supplementary Fig. S3).
Relative expression of MCP-1 (Ccl2) transcripts in
infarcted hearts treated with Map4k4-siRNA-GeRPs
was 68% lower at 3 days and 47% lower at 7 days
than in PBS-treated infarcted hearts (Fig. 5).
Impact of Map4k4-siRNA-loaded GeRP delivery
on extracellular matrix remodeling
GeRP delivery into infarct zones affected key matrix
and matricellular protein transcripts across the entire
heart (Fig. 5).14,15 Among the MMPs tested, transcripts
of Mmp1 and Mmp9 were both substantially reduced in
GeRP-treated hearts by day 3, by 71% and 88%, respec-
tively, versus PBS-treated, infarcted hearts. By day 7,
levels of both were in line with infarcted controls. In
GeRP-treated hearts, transcripts of Mmp12 were 85%
lower than in infarcted controls by day 7, effectively
at noninfarcted baseline levels. Mmp2 was not altered.
The proteoglycan versican and its binding partner,
HA, are primary components of the provisional matrix
produced by infiltrating myeloid cells, both highly
expressed and colocalized in infarct areas.16–18 Versi-
can (Vcan) transcription in GeRP-treated hearts was
reduced by 56% at 3 days, and by 61% at 7 days versus
infarcted controls ( p < 0.05). Effects on HA appeared
to be mediated through early decreases in the HA syn-
thases, Has1 and Has2, whereas Hyal1, encoding
the enzyme for HA degradation, was essentially un-
changed. Transcription of cell-surface HA receptor
gene, Cd44, was also halved at 3 days in GeRP-treated
hearts (47% decrease, p = 0.001 vs. PBS-treated con-
trols), which reversed by 7 days. The consequences of
FIG. 3. Relative Map4k4 gene expression after
acute myocardial infarction and GeRP delivery
of Map4k4 siRNA. Abundance of Map4k4 RNA in
acutely infarcted hearts injected immediately
after infarction with a single dose of PBS
(vehicle, dark gray) or GeRPs containing Map4k4
siRNA (light gray). Data are presented as mean
values (– SEM) relative to expression in hearts
without infarction or surgery as normal controls.
*p < 0.001 versus PBS-treated infarcted hearts at
7 days. Map4k4, mitogen-activated protein
kinase kinase kinase kinase 4.
FIG. 4. Relative IL-1b and TNF-a gene
transcription after acute infarction and GeRP
delivery of Map4k4 siRNA. Relative abundance of
Il1b and Tnf mRNA in infarcted hearts treated
with injection of PBS (dark gray) versus GeRPs
containing siRNA to Map4k4 (light gray) at 3 and
7 days after infarction and intramyocardial
injection. Values are expressed as mean fold
changes (– SEM) relative to normal noninfarcted
control hearts. *p = 0.06 versus PBS-treated
infarcted hearts at 3 days; **p = 0.05 versus PBS-
treated infarcted hearts at 7 days. IL, interleukin;
mRNA, messenger RNA.
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FIG. 5. Relative gene transcription for factors related to infarct healing following acute infarction and GeRP
delivery of Map4k4 siRNA. Relative abundance of mRNA across whole infarcted hearts treated with injection of
PBS (dark gray) versus GeRPs containing siRNA to Map4k4 (light gray) at 3 and 7 days after acute infarction
and intramyocardial injection. All values are expressed as mean fold changes (– SEM) relative to normal
noninfarcted control hearts. *p < 0.05 versus PBS-treated infarcted hearts at the same time point; **p < 0.001
versus PBS-treated infarcted hearts at the same time point; {p = 0.08 versus PBS-treated hearts on the given
day; {p < 0.05 versus PBS-treated hearts at 3 days; xp = 0.05 versus GeRP-treated hearts at 3 days.
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these transcriptional changes on extracellular matrix
deposition were further evaluated by HA accumulation
on histology in 7-day heart specimens. Abundant HA
expression was seen in the provisional matrix within
the infarct region in PBS-injected hearts, but was
hardly detectable in infarcts injected with Map4k4-
siRNA-loaded GeRPs (Fig. 6).
Profibrotic factors TGF-b1 and CTGF were both al-
tered by GeRP-delivered Map4k4 siRNA. TGF-b1
(Tgfb1) transcripts in hearts injected with Map4k4-
siRNA-loaded GeRPs were reduced by 59% at 3 days,
and by 65% at 7 days versus infarcted controls ( p = 0.03,
Fig. 5). Ctgf mRNA levels in GeRP-treated hearts were
58% lower at 3 days, and, by 7 days, CTGF expression
was inhibited by 85% ( p = 0.08). The postinfarct surge
in fibronectin (Fn1) expression was also prevented by
Map4k4-siRNA-GeRPs with a 75% lower level seen at 3
days ( p = 0.04 vs. PBS-treated hearts). GeRP treatment ad-
ditionally reduced expression of both collagen I (Col1a1)
and III (Col3a1) genes at 3 days (by 69% [p < 0.0001]
and 58% [p = 0.0002], respectively, vs. PBS controls). By
day 7, fibronectin and collagens I and III expression levels
were equivalent to those in infarcted PBS-treated hearts.
Postinfarct cell–matrix interactions are orchestrated by
regulatory matricellular glycoproteins such as periostin,
tenascin-c, and SPARC,19 all substantially diminished
by GeRP treatment. Gene expression of the collagen-
binding matricellular protein, SPARC, was reduced
by 81% at 3 days ( p = 0.08 vs. PBS-treated hearts),
tenascin-c by 87% ( p < 0.0001), and periostin by 89%
( p < 0.0001). By day 7, SPARC (Sparc) and tenascin-c
(Tnc) had been restored to standard postinfarct levels,
whereas periostin (Postn) transcription remained sig-
nificantly suppressed (89% reduction, p = 0.005 vs.
PBS-treated infarcted hearts).
Between days 4 and 8 after AMI, late-appearing factors
are also elaborated, here represented by IGF-1 and IL-
10.20–22 IGF-1 (Igf1) expression levels increased mark-
edly between days 3 and 7 in both PBS-treated and
GeRP-treated infarcted hearts (each p £ 0.05; Fig. 5).
A similar phenomenon was observed with IL-10 (Il10),
but increases did not reach significance at this sample
size. In GeRP-treated hearts, although Igf1 and Il10 tran-
scripts increased by 85% and 65%, respectively, between
days 3 and 7, levels remained lower than in PBS-treated
infarcted hearts at day 7. Even so, these levels were still
effectively doubled over those in noninfarcted controls.
Intramyocardial injection of GeRPs
was not associated with early ventricular rupture
No animals undergoing intramyocardial GeRP injec-
tions with Map4k4-directed siRNA had evidence of
ventricular rupture by 7 days.
Discussion
Previous trafficking studies have shown that few intra-
cardiac macrophages exit the heart after AMI.13
Instead, they largely remain within the heart and die
FIG. 6. Myocardial HA content on histology at 7 days after acute infarction. Biotin-conjugated HA-binding
protein (red) was used to visualize HA deposition in infarct areas in representative cross-sections of whole
hearts at 7 days after infarction and GeRP or PBS injections. Extensive HA accumulation was found in the
infarct area in PBS-treated hearts, consistent with an HA-rich (proinflammatory) provisional matrix (A),
whereas minimal HA deposition was seen in infarcts treated with GeRPs containing Map4k4 siRNA (B). GeRP
particles within the infarct area were identified by their incorporated fluorescein labels (green), as seen in
the GeRP-treated heart (B), but not present in the PBS-treated heart (A). HA, hyaluronan.
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in situ.13,23 Here, similarly low rates of systemic dis-
semination were confirmed among the intracardiac
macrophages that had phagocytosed infarct-injected
GeRP particles. We capitalized on this inherent ten-
dency for heart retention of differentiated macrophages
to develop a method for in situ modification of the in-
farct microenvironment using infarct-injected GeRPs
as a platform for siRNA delivery.
Other laboratories have utilized intravenous
delivery of siRNA-containing nanoparticles to target
postinfarct myocardial monocyte populations.24–27
After intravenous delivery, the largest populations
of particle-containing cells were found in the spleen,
liver, kidney, lymph nodes, and marrow, changing
splenic monocyte expression and raising the potential
for systemic immune effects. In comparison, direct
intramyocardial particle delivery might provide a
means to selectively modify the infarct microenviron-
ment with less risk of off-target accumulation and
consequences.
The 69–89% relative reductions in transcripts for
Map4k4, IL-1b, and TNF-a achieved at 3 days after a
single intramyocardial injection of siRNA-loaded
GeRPs were consistent with those reported in perito-
neal macrophages following a week of oral GeRP dos-
ing.4 More profound inhibition of whole-heart Map4k4
expression was not expected, given that (nontargeted)
cardiomyocytes also produce Map4k4.28 Peak siRNA
effects at 3 days, with persistence to 7 days in several
instances (Map4k4, IL-1b, versican, TGF-b, CTGF,
periostin), were in line with an expected half-life of 8
days for GeRP-delivered siRNA in tissues.4
Macrophage phenotypes across the entire heart
were not markedly changed, although leukocyte pop-
ulations within the infarct, i.e., at the site of GeRP de-
livery, were not specifically examined. Consistent with
the goal of maintaining macrophage viability, phago-
cytosis of GeRP microparticles and/or Map4k4 siRNA
did not result in appreciable macrophage depletion.
Rather, substantial functional alterations in the secre-
tome were seen across the myocardium. Of note, a
single dose of intramyocardial Map4k4-siRNA-loaded
GeRPs reduced the transcription of a surprisingly
broad spectrum of factors with relevance for infarct
healing. MCP-1 and MMP-9 facilitate inflamma-
tory cell recruitment from the circulation,29–31
whereas versican and HA mediate inflammatory cell
trafficking through the infarct matrix.16–19,32 MMPs
actuate matrix degradation,33 whereas TGF-b,34
CTGF,35 fibronectin,36 tenascin-c,37 SPARC,38,39 and
periostin40–42 all contribute to myofibroblast activa-
tion, collagen deposition, and cardiac fibrosis.
Together, diminished expression of this complemen-
tary combination of factors should predispose toward
a less inflammatory provisional matrix, preservation
of matrix structural integrity, and reduced risk for
late fibrosis. Supporting this premise was the marked
reduction in HA accumulation demonstrated in the
provisional matrix at 7 days in GeRP-treated hearts
(Fig. 6). However, definitive conclusions about the
value of early Map4k4 knockdown as a target in car-
diac remodeling cannot be drawn from these limited
pilots. Further experiments with longer durations of
follow-up in larger groups will be essential to deter-
mine final effects on late cardiac matrix structure
and ventricular function, as well as on macrophage
phenotypes and cytokine elaboration within the spe-
cific infarct microenvironment.
It is noteworthy that no instances of cardiac rupture
occurred by the 7-day time point. Earlier work has
shown that direct inhibition of IL-1b,43 TNF-a,44,45
MMP-9,31 MMP-12,46 periostin,47,48 and SPARC49
can each lead to ventricular dilation and/or rupture
within the first week postinfarct. The apparent relative
safety of GeRP delivery might be ascribed to the short
half-life of siRNA and to decremental reductions,
rather than elimination, of inflammatory mediators
and growth factors. In addition, structural factors,
such as the collagens, recovered to expected transcrip-
tion levels by 7 days. Although postinfarct rises in IGF-
1 expression were dampened (or delayed) by GeRP
treatment, they were still present, and the accompany-
ing phenotypic switch from proinflammatory to repar-
ative phenotypes in macrophages occurred unchecked.
Overall, these pilots demonstrate that macrophage
Map4k4 silencing appears a promising means to mod-
ulate the early infarct microenvironment after AMI. In
clinical translation, postinfarct GeRP delivery could be
accomplished with guided catheter-based intramyocar-
dial injections50 performed at the time of coronary
interventional procedures. More importantly, however,
this platform could be utilized for any limited-duration
RNAi strategy. If combined with cell transplantation
for heart failure, or incorporated into engineered ma-
trices, macrophage targets might be tailored toward
survival and/or proliferation of implanted cells. In con-
clusion, these experiments demonstrate that intramyo-
cardial GeRP injections may be a new and potentially
clinically relevant means for localized and selective
RNA delivery to intracardiac M/M populations.
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Map4k4 ¼ mitogen-activated protein kinase kinase kinase kinase 4
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